Hematology

The United States is becoming older, more diverse, and more overweight, and these changes may influence future trends in certain hematological cancers.

Patients and health care providers evaluated the use of an electronic patient-reported outcome (ePRO) intervention for use in a clinic setting for patients with relapsed or refractory multiple myeloma (RRMM).

Severe aplastic anemia used to have few options and mortality was high, but a new class of drugs offers some hope.

New real-world data confirms that carfilzomib, lenalidomide, and dexamethasone (KRd) are a safe and effective option for patients with relapsed or refractory multiple myeloma.

The oral selective inhibitor of nuclear export could provide a new therapeutic avenue in daratumumab-naive patients with relapsing refractory multiple myeloma (RRMM).

New research attempts to answer some of the mystery related to the causes and impact of hypercalcemia in patients with newly diagnosed multiple myeloma.

New research suggests it’s not disruptive to give radiation therapy to patients who are awaiting CAR T-cell therapy for relapsed or refractory multiple myeloma.

Patients with newly diagnosed multiple myeloma often receive twice-weekly triplet regimens of carfilzomib, lenalidomide, and dexamethasone (KRd). New data suggest less frequent dosing can be equally successful.

A new study suggests a potential new marker that could be used to track response to therapy and disease progression in patients with multiple myeloma.

There did not appear to be any particular patient characteristics linked with best responses to carfilzomib in patients with multiple myeloma, with the exception of low serum lactate dehydrogenase.

Newer therapies have led to a boost in the number of patients with relapsed or refractory multiple myeloma (R/R MM) who are prescribed triplet regimens. As that shift has occurred, death rates appear to have dropped.

New data show that despite major improvements in survival rates in patients with multiple myeloma (MM), older patients with the malignancy have benefited less than younger patients.

Investigators may have found a minimally invasive way to predict which patients with multiple myeloma are about to experience a relapse.

Newly published data suggests most patients are opting for second- or third-generation tyrosine kinase inhibitors instead of a generic form of imatinib.

A new report confirms earlier research that colon perforation in multiple myeloma is associated with corticosteroids, though the exact cause of the apparent link is not known.

Newly diagnosed patients with multiple myeloma (MM) face a high risk of infection. A new study helps elucidate key risk factors.

A new review article said there are hurdles to bringing minimal residual disease (MRD) into the clinic as a decision-making tool, but the day is likely not far away.

A subset of patients with multiple myeloma (MM) are not eligible for the most effective therapies, but a new study suggests clinicians may be inaccurately defining that subset.

Proteasome inhibitors have brought major advances in the treatment of multiple myeloma (MM), but eventual drug resistance remains a serious hurdle.

FDA will review the first chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of multiple myeloma (MM) in adults who have not responded or have relapsed after at least 3 other therapies.

A study of patients with multiple myeloma in China found many do not have access to a caregiver and most have to travel to another city to receive treatment.

Sickle cell disease is a costly disease for patients, but when those patients suffer from end-organ damage, the costs jump significantly.

A new study suggests stringent complete response is less meaningful than minimal residual disease status when evaluating patients with multiple myeloma.

New data suggests a patient’s education level can be an important factor in the disease outcomes of patients with multiple myeloma.

A new analysis found patients with high-cytogenetic-risk multiple myeloma benefitted from adding daratumumab to their therapy.

A new analysis finds therapeutic plasma exchange has become more costly, and more common among patients with multiple myeloma.

A new opinion article suggests minimal residual disease (MRD) is not yet ready for “prime time” in the clinic, even though it’s already making a major impact on clinical trials.

Evidence-Based Oncology regulatory updates for August 2020 feature coverage of Kite Pharma's new CAR T-cell therapy and selinexor in DLBCL.

Investigators have made tremendous strides improving patient care in multiple myeloma (MM), but the authors of a new review article say much more work is needed.

Clinical updates for August 2020 featured in Evidence-Based Oncology.